NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Monday,Benzinga reports. The brokerage currently has a $31.00 price target on the stock.

A number of other research firms also recently weighed in on NRXP. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $28.50.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $2.72 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The stock’s 50 day simple moving average is $3.11 and its two-hundred day simple moving average is $2.61. The stock has a market cap of $47.03 million, a price-to-earnings ratio of -1.35 and a beta of 1.59.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The firm had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.14 million. On average, analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of NRXP. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after purchasing an additional 993,401 shares during the last quarter. AdvisorShares Investments LLC lifted its stake in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares in the last quarter. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $61,000. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $56,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $33,000. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.